405173-97-9

Basic information

• Product Name: 2-(2-Chloroethyl)benzimidazole
• Synonyms: 2-(2-CHLOROETHYL)BENZIMIDAZOLE;1H-Benzimidazole,2-(2-chloroethyl)-(9CI);2-(2-cloroethyl)benzimidazole;2-(2-Chloroethyl)-1H-benzimidazole hydrochloride;2-(2-Chloroethyl)-1H-benzo[d]imidazole;1H-Benzimidazole, 2-(2-chloroethyl)-;2-(2-Chloroethyl)-1H-benzimidazole
• CAS NO: 405173-97-9
• Molecular Formula: C₉H₉ClN₂
• Molecular Weight: 180.63
• Product Categories: BENZIMIDAZOLE
• Mol File: 405173-97-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 387.696 °C at 760 mmHg
• Flash Point: 220.369 °C
• Appearance: /
• Density: 1.297 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.653
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-(2-Chloroethyl)benzimidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2-Chloroethyl)benzimidazole(405173-97-9)
• EPA Substance Registry System: 2-(2-Chloroethyl)benzimidazole(405173-97-9)

Safety Data

• Hazardous Substances Data: 405173-97-9(Hazardous Substances Data)

Usage

General Description

2-(2-Chloroethyl)benzimidazole is a chemical compound with the molecular formula C9H8ClN2. It belongs to the class of benzimidazole derivatives and contains a chloroethyl group. 2-(2-Chloroethyl)benzimidazole has potential use in the pharmaceutical industry as it has been studied for its potential anti-cancer properties. It is also used as a building block in organic synthesis and chemical research. 2-(2-Chloroethyl)benzimidazole is a reactive compound that should be handled with caution due to its potential to cause skin and eye irritation. It is important to use appropriate protective equipment and handling procedures when working with this chemical.

InChI:InChI=1/C9H9ClN2/c10-6-5-9-11-7-3-1-2-4-8(7)12-9/h1-4H,5-6H2,(H,11,12)

Upstream product

• 590-92-1 3-Bromopropionic acid 
• 95-54-5 1,2-diamino-benzene 
• 21367-89-5 3-Chlorpropionimidsaeure-aethylester-hydrochlorid 
• 107-94-8 chloropropionic acid 
• 51036-80-7 2-(2-ethoxy-ethyl)-1H-benzimidazole 

Downstream Products

• 405173-98-0 tert-butyl 2-(2-chloroethyl)-1H-benzo[d]imidazole-1-carboxylate 
• 121949-29-9 2-<2'-(benzimidazol-2''-yl)ethylthio>ethylamine dihydrochloride 

Relevant articles and documents

Deglycase-activity oriented screening to identify DJ-1 inhibitors

The oncoprotein and Parkinson's disease-associated enzyme DJ-1/PARK7 has emerged as a promiscuous deglycase that can remove methylglyoxal-induced glycation adducts from both proteins and nucleotides. However, dissecting its structural and enzymatic functions remains a challenge due to the lack of potent, specific, and pharmacokinetically stable inhibitors targeting its catalytic site (including Cys106). To evaluate potential drug-like leads against DJ-1, we leveraged its deglycase activity in an enzyme-coupled, fluorescence lactate-detection assay based on the recent understanding of its deglycation mechanism. In addition, we developed assays to directly evaluate DJ-1's esterase activity using both colorimetric and fluorescent substrates. The resulting optimized assay was used to evaluate a library of potential reversible and irreversible DJ-1 inhibitors. The deglycase activity-oriented screening strategy described herein establishes a new platform for the discovery of potential anti-cancer drugs.

SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS

The invention provides a compound having the structure (I), wherein A is a substituted or unsubstituted ring; Z is present or absent and when present is (II), wherein n is 0, 1, 2, 3, or 4; Y is -(CR11R12)-, -NH(CR11R12)- or -O(CR11R12)- wherein R11 and R12 are each hydrogen or combine to form a carbonyl; and wherein R1 to R10 are herein as described.

Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction

A new class of agents with potential utility for the treatment of erectile dysfunction has been discovered, guided by the hypothesis that selective D 4 agonists are erectogenic but devoid of the side effects typically associated with dopaminergic agents. The lead agent 2-(4-pyridin-2-ylpiperazin- 1-ylmethyl)-1H-benzimidazole (1, ABT-724) was discovered by optimization of a series of benzimidazole arylpiperazines. This highly selective D4 agonist was found to be very potent and efficacious in vivo, eliciting penile erections in rats at a dose of 0.03 μmol/kg, with a positive response rate of 77% erectile incidence. Even at high doses, it was devoid of side effects in animal models of central nervous system behaviors, emesis, or nausea. The structure-activity relationship of the parent benzimidazole series leading to 1 is described, with the detailed in vitro and in vivo profiles described. Distinctive structural features were discovered that are associated with D 4 selective agonism in this series of analogues.